Characterization of the genetic profile of CYP2C19 in two South African populations

Pharmacogenomics

Volumn 11, Issue 8, 2010, Pages 1095-1103

  Drögemöller, Britt I ^a   Wright, Galen E B ^a   Niehaus, Dana J H ^a   Koen, Liezl ^a   Malan, Stefanie ^a   Da Silva, Danielle M ^a   Hillermann Rebello, Renate ^a   La Grange, Anthony M ^a   Venter, Mauritz ^a   Warnich, Louise ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Cape Mixed Ancestry; CYP2C19; pharmacogenetics; South Africa; Xhosa

Indexed keywords

CYTOCHROME P450 2C19; OCTAMER TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2;

AFRICAN AMERICAN; ARTICLE; BINDING SITE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE CONSTRUCT; GENE FREQUENCY; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POPULATION GENETICS; RACE DIFFERENCE; REPORTER GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AFRICA;

AFRICAN CONTINENTAL ANCESTRY GROUP; ARYL HYDROCARBON HYDROXYLASES; BASE SEQUENCE; CELL LINE, TUMOR; COHORT STUDIES; GENES, REPORTER; GENOTYPE; HUMANS; LUCIFERASES; METABOLIC DETOXICATION, PHASE I; MOLECULAR SEQUENCE DATA; PHARMACOGENETICS; PLASMIDS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SOUTH AFRICA; TRANSFECTION;

EID: 77955591826     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.90     Document Type: Article

References (41)

1. Wester K, Jonnson AK, Sigset O, Druid H, Hagg S: Incidence of fatal adverse drug reactions: a population based study. Br. J. Clin. Pharmacol. 65, 573-579 (2008).
2. Allison M: Is personalized medicine fnally arriving? Nat. Biotechnol. 26, 509-517 (2008).
3. Ingelman-Sundberg M: Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, the present and future. Trends Pharmacol. Sci. 25, 193-200 (2004).
4. Oscarson M: Pharmacogenetics of drug metabolizing enzymes: importance for personalised medicine. Clin. Chem. Lab. Med. 41, 573-580 (2003).
5. Goldstein JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52, 349-355 (2001).
6. Andersson T, Flockhart DA, Goldstein DB et al.: Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin. Pharmacol. Ther. 78, 559-581 (2005).
7. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J: Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br. J. Clin. Pharmacol. 69, 222-230 (2010).
8. Janha RE, Sisay-Joof F, Hamid-Adiamoh M et al.: Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians. Pharmacogenomics 10(9), 1423-1431 (2009).
9. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A: Pharmacogenetic variation at CYP2C9, CYP2C19 and CYP2D6 at global and microgeographic scales. Pharmacogenet. Genomics 19, 170-179 (2009).
10. Wright GEB, Niehaus DJH, Drögemöller BI, Koen L, Warnich L: Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann. Hum. Genet. 74(4), 340-350 (2010).
11. Mwenifumbo JC, Zhou Q, Benowitz NL, Sellers EM, Tyndale RF: New CYP2A6 gene deletion and conversion variants in a population of black African descent. Pharmacogenomics 11(2), 189-198 (2010).
12. Tishkoff SA, Reed FA, Friedlaender FR et al.: The genetic structure and history of Africans and African Americans. Science 324, 1035-1044 (2009).
13. Dandara C, Masimirembwa CM, Magimba A et al.: Genetic polymorphism of CYP2D6 and CYP2C19 in East-and Southern African populations including psychiatric patients. Eur. J. Clin. Pharmacol. 57, 11-17 (2001).
14. Matimba A, Del-Favero J, van Broeckhoven C, Masimirembwa C: Novel variants of major drug-metabolizing enzyme genes in diverse African populations and their predicted functional effects. Hum. Genomics 3, 169-190 (2009).
15. Ehret C: Bantu expansions: re-envisioning a central problem of early African history. Int. J. Afr. Hist. Stud. 34, 5-41 (2001).
16. Lane AB, Soodyall H, Arndt S et al.: Genetic substructure in South African Bantu-speakers: evidence from autosomal DNA and Y-chromosome studies. Am. J. Phys. Anthropol. 119, 175-185 (2002).
17. Patterson N, Petersen DC, van der Ross RE et al.: Genetic structure of a unique admixed population: implications for medical research. Hum. Mol. Genet. 19, 411-419 (2010).
18. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215 (1988).
19. Ng PC, Henikoff S: SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812-3814 (2003).
20. Ramensky V, Bork P, Sunyaev S: Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 30, 3894-3900 (2002).
21. Brunak S, Engelbrecht J, Knudsen S: Prediction of human mRNA donor and acceptor sites from the DNA sequence. J. Mol. Biol. 220, 49-65 (1991).
22. Dogan RI, Getoor L, Wilbur WJ, Mount SM: SplicePort: an interactive splice-site analysis tool. Nucleic Acids Res. 35, 285-291 (2007).
23. Kel AE, Gössling E, Reuter I, Cheremushkin E, Kel-Margoulis OV, Wingender E: MATCH: a tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res. 31, 3576-3579 (2003).
24. Quandt K, Frech K, Karas H, Wingender E, Werner T: MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 23, 4878-4884 (1995).
25. Zuker M: Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406-3415 (2003).
26. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
27. Guengerich PF: Human cytochrome P450 enzymes. In: Cytochrome P450: Structure, Mechanism and Biochemistry. 3rd Edition. Oritz de Montellano PR (Ed.). Plenum Publishers, NY, USA, 378 (2005).
28. Kearns GL, Leeder JS, Gaedigk A: Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab. Dispos. 38(6), 894-897 (2010).
29. Gaedigk A, Coetsee C: The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur. J. Clin. Pharmacol. 64, 465-475 (2008).
30. Arefayene M, Skaar TC, Zhao X et al.: Sequence diversity and functional characterization of the 5́-regulatory region of human CYP2C19. Pharmacogenetics 13, 199-206 (2003).
31. Chen Y, Goldstein JA: The transcriptional regulation of the human CYP2C genes. Curr. Drug Metab. 10, 567-578 (2009).
32. Bhat R, Weaver JA, Sterling KM, Bresnick E: Nuclear transcription factor Oct-1 binds to the 5́ upstream region of CYP1A1 and negatively regulates its expression. Int. J. Biochem. Cell Biol. 28, 217-227 (1996).
33. Fiala-Beer E, Lee AC, Murray M: Regulation of the rat cyp2A4 gene promoter by c-Jun and octamer binding protein-1. Int. J. Biochem. Cell. Biol. 39, 1235-1247 (2007).
34. Mwinyi J, Hofmann Y, Pedersen RS et al.: The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression. Life Sci. 86, 699-706 (2010).
35. Blaisdell J, Mohrenweiser H, Jackson J et al.: Identifcation and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12, 703-711 (2002).
36. Rasmussen H, Werge T: Misclassifcation of allele CYP2C19*10 as CYP2C19*2 by a commonly used PCR-RFLP procedure. Genet. Test. 12, 57-58 (2008).
37. Ellis KJ, Stouffer GA, McLeod HL, Lee CR: Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics 10, 1799-1817 (2009).
38. Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI: Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br. J. Clin. Pharmacol. 65, 396-406 (2007).
39. Jones AE, Brown KC, Werner RE et al.: Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur. J. Clin. Pharmacol. 66(5), 475-485 (2010).
40. Chen L, Qin S, Xie J et al.: Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 9, 691-702 (2008).
41. Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG: Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics 10, 43-49 (2009).